A three-judge panel of the United States Court of Appeals for the Second Circuit in Manhattan ruled on December 5, 2012 that a drug sales representative who was criminally prosecuted for making off-label promotional statements about Xyrem had suffered a violation of his First Amendment right to freedom of speech.
independent record label | Record label | Independent record label | Black Label Society | ECM (record label) | Drag City (record label) | private label | Orfeo (record label) | Doremi (record label) | White-label product | White label | white label | Studio One (record label) | Multiprotocol Label Switching | European Union energy label | Big Cat Records (U.S. record label) | Zone 4 (record label) | Warp (record label) | Warning label | Under Fire (record label) | The Label Maker | Tangerine (label) | Supreme Intelligence (record label) | Soma Records (U.S. label) | Smart label | Reverberation (record label) | Record Label | Private label | off-label use | Nova Zembla (record label) |
In 1971, a New England Journal of Medicine editorial calling attention to previously published studies on the use of DES as a postcoital contraceptive at Yale University, and a large study published in JAMA on the use of DES as a postcoital contraceptive at the University of Michigan, led to off-label use of DES as a postcoital contraceptive becoming prevalent at many university health services.